Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Jade Biosciences ( (JBIO) ) just unveiled an announcement.
Jade Biosciences released its unaudited financial statements for the first quarter of 2025, revealing a net loss of $38.169 million. The company also updated its corporate presentation on May 14, 2025, which is now available on its website.
The most recent analyst rating on (JBIO) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Jade Biosciences stock, see the JBIO Stock Forecast page.
Spark’s Take on JBIO Stock
According to Spark, TipRanks’ AI Analyst, JBIO is a Underperform.
Aerovate Therapeutics’ stock score reflects substantial financial challenges, including zero revenue and growing losses, which heavily weigh on the overall score. While there is positive momentum in technical analysis and significant corporate events such as the merger with Jade Biosciences, the negative valuation and financial instability are major concerns. The stock remains highly speculative with risks due to its financial performance.
To see Spark’s full report on JBIO stock, click here.
More about Jade Biosciences
Average Trading Volume: 52,290
Technical Sentiment Signal: Sell
Current Market Cap: $276.6M
For a thorough assessment of JBIO stock, go to TipRanks’ Stock Analysis page.